NEW YORK, NY – (PR Newswire – August 25, 2015)
New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates.
“Discovering five different types of the disease could change how they’re distinguished from one another and may even mean different treatments for each, targeted to the individual patient,” said Dr. Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York City.
Researchers analyzed 259 men with prostate cancer. Among the group of participants, 482 tumor, benign and germline samples were looked at. The researchers analyzed the samples and looked for genetic differences that made it so the researchers could categorize the study participants into groups regarding targeted treatments specific to their prostate cancer.
What they found was more than minimal differences among the tumors. They concluded that five different types of prostate cancer were found based on 100 genes. These genes demonstrated the risk of the disease progression, which was more accurate than the currently used Gleason score test and PSA test.
Prior research had shown six of the genes were linked to prostate cancer, however researchers noted in the published study that it turns out the other 94 genes had not been associated with prostate cancer until now.
“If five types of the disease exist, how does this change popular medical opinion on prostate cancerscreening? This may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,” noted Dr. Samadi.
While the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type. This could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.
Prostate Cancer Key Statistics:
The researchers said the analysis in their study is better at forecasting how prostate cancer will advance compared to the current diagnostic tests being used for prostate cancer such as the prostate specific antigen test and the Gleason score.
“These findings could lead to more optimized diagnostic testing on all aspects of the prostate cancer diagnosis process and brings full circle the coming approach to cancer being an individual disease based very much on the patient’s individual genetic profile,” said Dr. Samadi.
Get more of Dr. Samadi’s take on this study and its effect on the field of Prostate Cancer on Fox News Sunday Housecall.
Patients newly diagnosed with prostate cancer can contact world renowned prostate cancer surgeon and urologic oncologist, Dr. David Samadi, for a consultation or second opinion. For men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.
Visit ProstateCancer911.com and call 212.365.5000 to set up your consultation.
ABOUT DR. DAVID SAMADIDr. Samadi is a board certified urologic oncologist trained in open and traditional and laparoscopic surgery and is an expert in robotic prostate surgery. He is Chairman of Urology, Chief of Robotic Surgery at Lenox Hill Hospital and Professor of Urology at Hofstra North Shore-LIJ School of Medicine. He is also part of the Fox News Medical A Team as a medical correspondent and the Chief Medical Correspondent for am970 in New York City. He has dedicated his distinguished career to the early detection, diagnosis and treatment of prostate cancer and is considered one of the most prominent surgeons in his field. Learn more at prostatecancer911.com. Visit Dr. Samadi’s blog at SamadiMD.com. For more comprehensive information about prostate cancer, detecting prostate cancer, how to live with prostate cancer, and how to help support the fight against prostate cancer, please visit samadifoundation.orgNews